SINT News & Events

The company states: "SINTX Technologies announced the successful completion of the first-in-human surgical procedure utilizing its FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System, marking a major clinical and commercial milestone in the Company's expansion into the global orthopedic device market. The procedure represents SINTX's entry into the foot and ankle reconstruction segment, a significant and growing category within the multi-billion-dollar orthopedic implant market, and underscores the Company's strategy to commercialize its proprietary silicon nitride biomaterial platform across multiple surgical applications."

Sintx Technologies announced the appointment of Ryan Elmore as President of SINTX Technologies, effective March 16, 2026. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc.

SINTX Technologies signed a supply agreement with Evonik to manufacture the Company's proprietary silicon nitride-PEEK compound engineered for AI-assisted additive manufacturing of patient-specific implants that will be produced using equipment already in place at SINTX's U.S.-based production facility. Under the agreement, EVONIK will produce SiN/PEEK compound leveraging its commercial-scale capability to SINTX's specifications, enabling the Company to immediately begin manufacturing AI-designed, 3D-printed, patient-specific implants. SINTX has already received physician requests to provide humanitarian-use vertebral body replacement implants for orthopedic and neurosurgical oncology patients following tumor resections in the spine. In addition, the Company intends to use the SiN/PEEK compound to support regulatory clearances of patient matched and traditional subtractive manufactured implantable devices.

Reports Q3 revenue $208k vs $799k last year. "We have aligned SINTX squarely behind near-term commercial milestones with our advanced biomaterial products," said Eric Olson, President and CEO of SINTX. "The 510(k) clearance for our SINAPTIC foot & ankle wedge system represents a pivotal milestone that validates our technology and establishes a scalable platform for future growth. We believe the decisive actions we have taken to monetize non-core assets, streamline facilities, and maintain prudent access to capital position the Company to execute this strategy effectively. The Company remains focused on advancing clinical leadership into sustainable product revenue opportunities, while building broader commercial utilization around silicon nitride's unique clinical advantages."